Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest privately held arts-and-crafts retailer with 1,072 stores targeting 1,500 US stores by 2026; $7.9B revenue in 2023; Oklahoma City-based; 100% family-owned with faith-based Sunday closure policy;
Hobby Lobby is the world's largest privately held arts-and-crafts retailer, founded in 1972 by David Green in Oklahoma City, Oklahoma. What started as a 300-square-foot picture frame shop in the Green family garage has grown into a national retail institution with a distinct identity rooted in Christian values. The company is 100% family-owned and famously closed on Sundays, a policy reflecting its faith-based operating philosophy.\n\nHobby Lobby's stores average 55,000 square feet and carry more than 80,000 products across crafts, fabric, floral, seasonal décor, frames, and art supplies. The company operates its own manufacturing and sourcing operations across Asia, contributing to its ability to offer deep, frequent discounts — typically 40% off on rotating categories. Hobby Lobby serves DIY enthusiasts, home decorators, teachers, and small craft business owners primarily in suburban and rural US markets. Its everyday low-price strategy and massive store format make it a destination retailer.\n\nHobby Lobby operates 1,072 stores across the United States and generated $7.9 billion in revenue in 2023. The company has an ambitious expansion plan targeting 1,500 US stores by 2026, representing nearly 40% growth from its current footprint. Despite competition from Amazon, Michaels, and JOANN, Hobby Lobby has maintained strong performance through its differentiated product mix, consistent promotional cadence, and loyal customer base among religious and craft communities.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.